News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB) And Elan Pharmaceuticals (ELN) Announce That FDA Will Extend Regulatory Review Period For The Reintroduction Of TYSABRI(R) For Multiple Sclerosis


3/22/2006 10:37:02 AM

CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--March 22, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that the U.S. Food and Drug Administration (FDA) informed the companies that the Agency will extend its regulatory review of TYSABRI(R) (natalizumab) as a treatment for multiple sclerosis by up to 90 days.

Read at BioSpace.com
Read at Sharewatch
Read at press release
Read at CCNMatthews
Read at AP

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES